cas 1297537-45-1|| where to buy 3-Acetyl-1H-pyrazole-5-carboxylic acid

Nombre del producto:3-Acetyl-1H-pyrazole-5-carboxylic acid

IUPAC Name:3-acetyl-1H-pyrazole-5-carboxylic acid

Unidad de embalaje	Stock disponible	Precio($)
CM281127-5g	in stock	Ǒȅ
CM281127-25g	in stock	ŪȖŞ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1297537-45-1 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1297537-45-1; Fórmula molecular:C6H6N2O3; Punto de fusión:-; Código de sonrisas:O=C(C1=CC(C(C)=O)=NN1)O; Densidad:

: Número de catálogo:CM281127; Peso molecular:154.13; Punto de ebullición:; Nº Mdl:MFCD05864511; Almacenamiento:Store at 2-8°C.

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Darolutamide; Bayer announced that its Phase 3 clinical ARANOTE trial met its primary endpoint. Its oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) combined with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). NUBEQA® (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to androgen receptors with high affinity and exhibits strong antagonistic activity, thereby inhibiting receptor function and the growth of prostate cancer cells.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.